AI assistant
Sending…
Nuvectis Pharma, Inc. — Director's Dealing 2022
Feb 8, 2022
33912_dirs_2022-02-08_4d0ed984-047b-4bca-88d9-bff7599afacc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-02-08
Reporting Person: Kaplan Matthew L. (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 32760 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options | $3.05 | 2032-09-02 | Common stock (9750) | Direct | |
| Options | $3.05 | 2033-09-02 | Common stock (9750) | Direct | |
| Options | $3.05 | 2034-09-02 | Common stock (9750) | Direct |
More from Nuvectis Pharma, Inc.
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Regulatory Filings
2026
Feb 23
Capital/Financing Update
2026
Feb 13
Earnings Release
2026
Feb 11
Annual Report
2026
Feb 11
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9
Director's Dealing
2026
Jan 9